Innovative Scope in Biotech Business

Show simple item record

dc.contributor.author	Valentin, Finn	en_US
dc.contributor.author	Reichstein, Toke	en_US
dc.date.accessioned	2009-02-04T10:26:25Z
dc.date.available	2009-02-04T10:26:25Z
dc.date.issued	2007-12-10T00:00:00Z	en_US
dc.identifier.isbn	9788791549212	en_US
dc.identifier.uri	http://hdl.handle.net/10398/7205
dc.description.abstract	Using extensive patent data on Scandinavian Biotech firms together with associated firm level data, this paper explores factors that drive the innovative scope of biotech firms. Collaborating with pharmaceutical firms, universities and other dedicated biotech firms proves beneficiary in introducing innovations broadening the innovation scope of biotech firms. Contrasting large and small molecules research firms exhibit noteworthy differences in the type of collaboration partner that allows the firm to expand its innovative scope. This suggests that biotech firms need to align the partner type with its science base if the goal is to produce patents beyond the firms technological boundary. Additionally, we find that outsourcing and acquisition of innovations increase their scope, lending support to the view that outsourced R&D expands the boundary of the firm’s innovative search.	en_US
dc.format.extent	27 s.	en_US
dc.language	eng	en_US
dc.relation.ispartofseries	Working paper;2007-5	en_US
dc.title	Innovative Scope in Biotech Business	en_US
dc.type	wp	en_US
dc.accessionstatus	modt07dec10 nijemo	en_US
dc.contributor.corporation	Copenhagen Business School. CBS	en_US
dc.contributor.department	Research Centre on Biotech Business	en_US
dc.contributor.departmentshort	BIOTECH	en_US
dc.contributor.departmentuk	Research Centre on Biotech Business	en_US
dc.contributor.departmentukshort	BIOTECH	en_US
dc.idnumber	9788791549212	en_US
dc.publisher.city	København	en_US
dc.publisher.year	2007	en_US
dc.title.subtitle	Effects of Aligning Partner Types with the Firm's Science Base	en_US